Medical Services Advisory Committee - Applications Considered
- 1196.3 - Repetitive Transcranial Magnetic Stimulation (rTMS) for the treatment of depression (resubmission)
- 1353.1 – Measurement of calprotectin as a marker of bowel inflammation (resubmission)
- 1408 – A prognostic RT-qPCR test run locally for ER+ve/HER2-ve breast cancer that determines the risk of early and late metastasis in node negative and positive cancer under endocrine treatment
- 1492 – Non-Invasive Prenatal Testing (NIPT) for common trisomies (12, 18 and 3)
- 1512 – Apolipoprotein B testing for high risk cardiovascular disease risk assessment
- 1519.1 – Tisagenlecleucel (CTL019) for treatment of relapsed or refractory diffuse large B-cell lymphoma (resubmission)
- 1523 – Transluminal insertion, management, repositioning, and removal of an intravascular microaxial blood pump (Impella), for patients requiring mechanical circulatory support
- 1528 – Somatic tumour gene testing for the diagnosis of hydatidiform moles
- 1533 – Genome-wide microarray testing for pregnancies with major foetal structual abnormalities detected by ultrasound
- 1542 – Endovascular insertion of flow diversion device (FDD) for the treatment of unruptured intracranial aneurysms (UIAs)
- 1544 - Genome-wide microarray testing for people with multiple myeloma and chronic lymphocytic leukaemia
- 1546 - Abdominoplasty with repair of rectus diastasis (aka rectus divarication) following pregnancy
- 1554 - Testing of tumour tissue or blood to detect somatic or germline BRCA1 or BRCA2 gene mutations, in a patient with newly diagnosed, advanced (FIGO stage III-IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) to first-line platinum-based chemotherapy)
- 1555 - Endoscopic Sleeve Gastroplasty (ESG) for the treatment of patients with Class I and Class II obesity with comorbidities who have failed first-line treatments
- 1560 - 17p Deletion Testing by FISH for access to ibrutinib in patients with previously untreated chronic lymphoid leukaemia or small lymphocytic lymphoma
- 1562 - Streamlining Medicare Benefits Schedule items for Positron Emission Tomography (PET) project
- 1565 - Acquired hypogammaglobulinaemia secondary to haematological malignancies, or post-haemopoietic stem cell transplantation
- 1587 - Axicabtagene cilolecleucel YESCARTATM (CAR-T therapy) for the treatment of refractory or relapsed CD19 lymphoma
- 1606 - Request to amend existing MBS Item No 73341 (Fluorescence in situ hybridisation (FISH) test of tumour tissue from a patient with locally advanced or metastatic non-small cell lung cancer) to add brigatinib
- 1626 - Mentor textured breast implants and expanders compared with smooth breast implants and expanders on the Prostheses List